A glycosylated Fc‐fused glucagon‐like peptide‐1 receptor agonist exhibits equivalent glucose lowering to but fewer gastrointestinal side effects than dulaglutide

AIM: To evaluate the pharmacokinetic and pharmacodynamic properties of a novel glycosylated Fc‐fused glucagon‐like peptide‐1(GLP‐1‐gFc) receptor agonist with distinctive receptor binding affinity, designed to improve in vivo stability and safety relative to the commercial GLP‐1 analogue dulaglutide,...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Diabetes Obes Metab
Main Authors: An, In Bok, Byun, Mi Sun, Yang, Sang In, Choi, Yuri, Woo, Jung Won, Jang, Hak Chul, Sung, Young Chul
Formato: Artigo
Idioma:Inglês
Publicado em: Blackwell Publishing Ltd 2020
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7383507/
https://ncbi.nlm.nih.gov/pubmed/32314505
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/dom.14058
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados